Sign in
4/A

Changes in Ownership

Kalaris Therapeutics, Inc. Filed Acc 0000899243-22-034265

General Counsel sold 553 shares at $9.36 ($5,176)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Miller Edward General Counsel 2022-10-20 Sale −553 $9.36 $5,176 249,377 D: show line 1 in the form
Open-market sales · 553 sh · avg $9.36 · $5,176
Loading xslF345X03/doc4a.xml…